Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

27.00
EUR
-0.80
(-2.88%)
-5.57EPS
1.77BMarket Cap
Feb 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.66
1.94
1.58
1.79
0.92
1.64
- -
- -
- -
0.26
0.48
0.64
0.93
2.38
Basic EPS, GAAP
-2.83
-1.59
-3.15
-5.07
-6.75
-6.03
-6.86
-4.74
26.55
-4.23
-6.33
11.86
-7.12
-6.31
Free Cash Flow per Basic Share
-3.74
-1.83
-2.59
0.73
-6.22
-5.42
-6.38
-4.42
-6.83
-5.74
-5.65
-6.89
-6.68
-5.69
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.21
11.44
9.16
8.49
7.69
11.81
9.36
5.77
23.78
20
14.5
26.96
20.41
16.38
Tangible Book Value per Share
4.21
11.44
9.16
8.49
7.69
11.81
9.36
5.77
23.78
20
14.5
26.96
20.41
16.38
Basic Weighted Avg Shares
15
34
37
39
47
57
60
69
60
55
56
57
58
59
Sales/Revenue/Turnover
26
65
59
70
43
94
- -
- -
- -
14
27
36
54
141
Operating Margin (%)
-152.2
-82.83
-200.78
-287.57
-745.84
-384.03
- -
- -
- -
-2,732.07
-1,459.52
-1,166.47
-873.87
-297.72
Depreciation Expense
1
1
3
6
6
7
8
10
9
9
7
6
5
5
Net Income, GAAP
-39
-54
-118
-198
-315
-346
-411
-327
1,605
-232
-352
674
-413
-373
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.16
- -
- -
Profit Margin (%)
-154.25
-81.86
-199.14
-283.97
-731.6
-366.61
- -
- -
- -
-1,627.82
-1,312.63
1,845.92
-764.01
-264.76
Working Capital
133
298
284
471
350
520
519
542
1,004
770
766
884
860
675
LT Debt
- -
- -
- -
- -
- -
- -
107
98
86
72
57
40
22
7
Total Equity
131
424
345
359
376
688
641
400
1,292
1,101
811
1,541
1,193
979
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-32.19
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
54.31
- -
- -
Return on Common Equity (%)
- -
-19.25
-30.6
-56.41
-85.73
-65.1
-61.97
-62.95
189.74
-19.37
-36.83
57.29
-30.2
-32.95

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
19
20
LT Borrowings
- -
- -
- -
LT Finance Leases
17
12
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
60
60
Market Capitalization
1,989
2,220
2,006

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
835
718
752
Cash, Cash Equivalents & STI
114
618
630
Accounts Receivable, Net
16
20
25
Inventories
35
30
38
Total Current Liabilities
59
70
78
Payables & Accruals
- -
36
39
ST Debt
- -
19
20
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.7%
49.94%
-22.57%
Free Cash Flow
-119.63%
7.01%
-1.08%
Net Income, GAAP
-96.98%
-221.07%
-161.27%
Sales/Revenue/Turnover
- -
- -
48.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
9
9
11
36
2025
9
12
13
20
54
2026
21
45
55
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.45
-1.69
16.65
-1.69
11.86
2025
-1.55
-1.93
-1.78
-1.85
-7.12
2026
-1.69
-1.69
-1.09
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Brian M. Goff
Full Time Employees
540
Sector
Health technology
Industry
Pharmaceuticals: major
Address
88 Sidney Street Cambridge MA United States 02139
IPO Date
Jul 24, 2013
Website
agios.com
Business
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing transformative therapies primarily in the field of cellular metabolism, with a near-term emphasis on rare diseases such as hemolytic and acquired anemias. Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios develops precision medicines including its flagship product, Pyrukynd (mitapivat), an oral activator of pyruvate kinase enzymes targeting hemolytic anemias such as pyruvate kinase deficiency and sickle cell disease. Its product portfolio also involves investigational candidates like tebapivat, a next-generation PK activator, and AG-236, aimed at addressing broader metabolic and hematologic disorders. The company’s offerings encompass small-molecule drugs and supportive patient services programs like myAgios to facilitate access and treatment adherence. Recent major developments include the positive results from the ACTIVATE-Kids Phase 3 study demonstrating the efficacy of mitapivat in pediatric patients with pyruvate kinase deficiency, establishing a pathway for pediatric label expansion. Agios is preparing for the U.S. commercial launch of Pyrukynd in multiple hemolytic anemia indications including sickle cell disease and thalassemia in 2026, supported by increased commercial infrastructure and headcount expansion. The company is advancing pipeline diversification with an IND filing planned for mid-2025 for AG-236 and Phase 2 trials for tebapivat in sickle cell disease, reinforcing its strategic objective to treat a broad spectrum of rare blood disorders through oral, disease-modifying therapies. Agios also concentrates on expanding its research into cancer metabolism as a complementary segment. Agios Pharmaceuticals operates primarily in the United States with its products addressing unmet needs in the rare genetic disease market and hematology segments. It leverages advanced technologies in metabolic pathway targeting, small molecule drug discovery, and clinical development. The company’s strategic alliances, regulatory progress, and patient-centric commercialization programs position it as a leader in the transformative rare disease therapy space. Its founding scientific focus on cellular metabolism continues to drive innovation across both rare hematologic diseases and oncology therapeutic areas. This comprehensive portfolio and recent clinical and commercial advances underline Agios’s commitment to providing long-term, disease-modifying treatments for patients with rare metabolic diseases and blood disorders.

Company News

  • Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript

  • What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

  • Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

  • Agios Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026

  • Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)

  • Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

  • Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

  • Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

  • AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

  • Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

  • Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO

  • Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages

  • AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year